Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
25 women students to receive internship, training, and mentorship in Life Sciences segment
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
Findings likely to generate hypotheses about potential new uses of drugs
Subscribe To Our Newsletter & Stay Updated
